10x Science

Name: 10x Science
Brand: 10x Science

AI Native

The AI-native platform for next-generation protein characterization.

Est 2025

LinkedIn 1K|Web traffic 1K|FTEs 4|HQ San Francisco, California, US

Published Jun 25, 2026

01Common complaints

1) You require a mature compliance posture today - If procurement requires public SOC 2 Type II, ISO 27001, or detailed security whitepapers and a published privacy policy, the vendor does not appear to provide these publicly as of the review date. 2) You require extensive third-party proof and references - If your evaluation requires multiple peer-reviewed case studies, large customer lists, or third-party validation studies, the vendor’s current public footprint is limited. 3) Your organization is tightly standardized on a single vendor ecosystem - If Thermo, Waters, or SCIEX end-to-end workflows are deeply embedded and validated, adding or replacing the analysis layer will require validation and integration effort. 4) Your use case is outside protein therapeutics characterization - The vendor’s public positioning is specific to protein therapeutics. For metabolomics, routine QC, or other non-protein MS use cases, specialist incumbent tools may be more appropriate.

Deal disqualifiers (poor fit)

Organizations requiring public SOC 2 or ISO 27001 documentation prior to procurement
Workflows requiring strictly on-premises deployment or detailed published architecture where vendor cannot demonstrate support
Teams needing a full LIMS/ELN and instrument control suite rather than an analysis acceleration layer

Publicly visible limitations

Public website content is limited; third-party scans have flagged missing dedicated pricing, terms, and some informational pages. This lack of public documentation can create trust and procurement barriers.

Roadmap and feature availability

No public product roadmap was found.

Scale limitations

Public materials do not include benchmarks on dataset sizes, number of spectra supported, runtime performance, or concurrency characteristics.

Security and compliance gaps

No publicly available SOC 2 or ISO certifications and limited public privacy/terms documentation were found during this review.

02Why they buy

Differentiators indicated in public sources

Vendor emphasizes analysis traceability and explainability intended to support regulated workflows.
Public reports describe automation of sequence lookup and interpretation workflows, including automated inference of protein identity from MS data.

Claims requiring verification

Vendor-provided claims such as major reductions in analysis time and specific labor cost savings are unverified in public sources and lack disclosed methodologies.

Areas where competitors hold advantages

Procurement and compliance readiness (documented security and validation artifacts)
Larger installed base and established validation practices
Broader integration across instruments and enterprise informatics

03Field reports

Important limitation: review-platform coverage is effectively absent

Because the company is recently founded, it has limited presence on mainstream B2B review platforms:

G2: No listing found for 10x Science specifically; searches surfaced unrelated products named “10X ERP.”
TrustRadius: No relevant listing found for 10x Science.
Gartner Peer Insights: No identifiable product profile or reviews found for 10x Science in accessible searches.

Available testimonials / quotes (primarily press and launch content)

1) TechCrunch reported an early user quote from a scientist at a contract analytical lab describing perceived productivity improvements and noting explainability and the platform’s assumptions compared with other AI tools. Sample quotes from press coverage (short excerpts): - "I ran a particular protein through it, and it just kind of figured out… what the protein probably was." - "This software is going to help keep that can of worms closed and just get them the answer…" 2) Startup accelerator launch material and vendor statements contain ROI and speed claims such as reduced analysis time and estimated time savings; these vendor-provided figures are unverified and should be treated as marketing claims.

What’s missing (and why it matters)

No broad set of user reviews across multiple organizations was found.
No independent benchmarks comparing the platform with incumbent tools (e.g., BioPharma Finder, UNIFI, BioPharmaView).
No public reference customers beyond those mentioned in press coverage.

1) TechCrunch-reported early usage (Rilas Technologies)

Press coverage describes an early use by a contract analytical lab. Evaluative notes:

What is useful: an independent practitioner perspective indicating early real-world use.
What is missing: quantified before/after metrics, dataset complexity details, error rates, and comparisons with results from incumbent software.
Independent verification: none publicly available.

2) Vendor / accelerator launch metrics (unverified)

Vendor and accelerator materials include claims such as substantial reductions in analysis time and a published monthly time-savings estimate. Critical evaluation:

No disclosed methodology, team size assumptions, labor rates, throughput, or baseline toolchain details.
No public customer names tied to these figures or third-party validation studies.

04Best fit

Likely best-fit organizations

Biotech and pharmaceutical companies conducting extensive MS-based protein therapeutics characterization
CROs and analytical service providers that need to scale characterization work across multiple projects or clients
Teams experiencing throughput bottlenecks due to limited expert analyst capacity

Company size (practical estimate)

Firms ranging from mid-size biotechs to large pharmaceutical organizations could find the platform relevant, though early adopters are likely to be growth-stage biotechs and CROs able to execute pilot programs quickly.

Roles / personas

Decision makers: Heads of Analytical Development, CMC leaders, Proteomics Core Directors, VP Platform/Technology, Informatics leads
End users: Mass spectrometry analysts, proteomics scientists, bioinformaticians, QA/CSV stakeholders

Qualification criteria (good fit)

High volume of LC-MS/MS characterization projects
Need for faster reporting and reproducible interpretations
Willingness to run formal comparative evaluations against incumbent workflows

05The pitch

What the product does (core value proposition)

10x Science describes itself as an AI-based protein characterization platform intended to accelerate and automate interpretation of mass spectrometry (MS) datasets used in biologics and therapeutic protein development. The company states that the platform can shorten manual, expert-driven interpretation and report generation (which may take weeks or months) to a much shorter timeframe, while providing analysis traceability intended to support regulated workflows. Key vendor statements and positioning: - Described in press materials as offering automated, explainable molecular characterization of protein therapeutics. - The company describes its approach as combining deterministic algorithms rooted in chemistry and biology with machine learning components that interpret data, with an emphasis on traceability for regulatory contexts.

Target market and market positioning

Target users appear to include: - Analytical scientists focused on biologics characterization (antibodies, engineered proteins, cell- and gene-therapy-associated proteins) - Contract research/analytical organizations (CROs) that run MS-based characterization for clients - Pharmaceutical and biotech R&D and CMC/analytical development teams - Academic labs and core facilities performing proteomics or protein therapeutic characterization Positioning: a software layer that runs on top of existing MS workflows to address downstream analysis and interpretation bottlenecks, rather than a replacement for MS instrumentation.

Get a comprehensive analysis of 10x Science including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →